

Henry C Marsh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/305000/publications.pdf>

Version: 2024-02-01

50
papers

2,900
citations

218677

26
h-index

206112

48
g-index

50
all docs

50
docs citations

50
times ranked

2784
citing authors

#	ARTICLE	IF	CITATIONS
1	Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	6
2	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. <i>Nature Communications</i> , 2020, 11, 5415.	12.8	85
3	A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells. <i>Journal of Immunology</i> , 2020, 205, 1867-1877.	0.8	19
4	Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2125-2137.	4.2	20
5	Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. <i>Nature Medicine</i> , 2019, 25, 814-824.	30.7	293
6	CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. <i>Journal of Immunology</i> , 2017, 199, 4110-4123.	0.8	37
7	Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2946-2954.	4.1	33
8	Expansion of Dendritic Cells Using FLT3 Ligand to Treat Glioblastoma. <i>Neurosurgery</i> , 2016, 63, 198-199.	1.1	0
9	Characterization of the human T cell response to in vitro CD27 costimulation with varilumab. , 2015, 3, 37.		54
10	Comparison of Complement Activity in Adult and Preterm Sheep Serum. <i>American Journal of Reproductive Immunology</i> , 2015, 73, 232-241.	1.2	3
11	Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine. <i>Cellular and Molecular Immunology</i> , 2015, 12, 719-728.	10.5	24
12	Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. <i>OncImmunology</i> , 2014, 3, e27255.	4.6	24
13	FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 309-313.	2.0	17
14	Complement activation is critical for placental ischemia-induced hypertension in the rat. <i>Molecular Immunology</i> , 2013, 56, 91-97.	2.2	44
15	Soluble CR1 Therapy Improves Complement Regulation in C3 Glomerulopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1820-1829.	6.1	80
16	Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice. <i>Journal of Immunology</i> , 2013, 191, 4174-4183.	0.8	90
17	Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia. <i>Clinical Cancer Research</i> , 2012, 18, 3812-3821.	7.0	63
18	Co-administration of a CpG adjuvant (VaxImmune™, CPG 7909) with CESTP vaccines increased immunogenicity in rabbits and mice. <i>Hum Vaccin</i> , 2009, 5, 79-84.	2.4	29

#	ARTICLE	IF	CITATIONS
19	The Partly Folded Back Solution Structure Arrangement of the 30 SCR Domains in Human Complement Receptor Type 1 (CR1) Permits Access to its C3b and C4b Ligands. <i>Journal of Molecular Biology</i> , 2008, 375, 102-118.	4.2	39
20	Beneficial Effects of Complement Inhibition With Soluble Complement Receptor 1 (TP10) During Cardiac Surgery: Is There a Gender Difference?. <i>Circulation</i> , 2007, 116, I-83-I-88.	1.6	23
21	Pre-clinical evaluation of an sLex-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke. <i>Journal of Medical Primatology</i> , 2007, 36, 375-380.	0.6	23
22	Preclinical evaluation of the neuroprotective effect of soluble complement receptor Type 1 in a nonhuman primate model of reperfused stroke. <i>Journal of Neurosurgery</i> , 2006, 105, 595-601.	1.6	26
23	Activation of the spinal cord complement cascade might contribute to mechanical allodynia induced by three animal models of spinal sensitization. <i>Journal of Pain</i> , 2005, 6, 174-183.	1.4	48
24	Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology. <i>Glycobiology</i> , 2004, 14, 883-893.	2.5	14
25	Soluble Human Complement Receptor 1 Limits Ischemic Damage in Cardiac Surgery Patients at High Risk Requiring Cardiopulmonary Bypass. <i>Circulation</i> , 2004, 110, I1274-9.	1.6	64
26	Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats. <i>Pain</i> , 2004, 110, 299-309.	4.2	124
27	Synthesis and Complement Inhibitory Activity of B/C/D-Ring Analogues of the Fungal Metabolite 6,7-Diformyl-3,4,4a,5,6,7,8,8a-octahydro-4,6,7-trihydroxy-2,5,8a-tetramethylspiro[1(2H)-naphthalene-2(3H)-benzofuran]. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2697-2705.	6.4	14
28	Characterization of N-linked oligosaccharides bearing sialyl Lewis x moieties on an alternatively glycosylated form of soluble complement receptor type 1 (sCR1). <i>Biotechnology and Applied Biochemistry</i> , 2000, 31, 5.	3.1	6
29	Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2106-2112.	2.4	304
30	Total Complement Inhibition. <i>Circulation</i> , 1999, 100, 1438-1442.	1.6	47
31	Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules. <i>Journal of Biological Chemistry</i> , 1999, 274, 11237-11244.	3.4	50
32	Reduction of myocardial infarct size with sCR1sLex, an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. <i>British Journal of Pharmacology</i> , 1999, 128, 945-952.	5.4	42
33	Neuronal Protection in Stroke by an sLex-Glycosylated Complement Inhibitory Protein. <i>Science</i> , 1999, 285, 595-599.	12.6	328
34	EFFECT OF COMPLEMENT INHIBITION WITH SOLUBLE COMPLEMENT RECEPTOR 1 ON PIG ALLOTRANSPLANT LUNG FUNCTION1. <i>Transplantation</i> , 1998, 66, 723-732.	1.0	44
35	EFFECT OF CONTINUOUS COMPLEMENT INHIBITION USING SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON SURVIVAL OF PIG-TO-PRIMATE CARDIAC XENOGRAFTS1. <i>Transplantation</i> , 1997, 63, 900-902.	1.0	74
36	COMPLEMENT ACTIVATION AS A CAUSE FOR PRIMARY GRAFT FAILURE IN AN ISOGENEIC RAT MODEL OF HYPOTHERMIC LUNG PRESERVATION AND TRANSPLANTATION. <i>Transplantation</i> , 1997, 64, 1248-1255.	1.0	48

#	ARTICLE	IF	CITATIONS
37	A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. <i>European Journal of Immunology</i> , 1996, 26, 1729-1735.	2.9	34
38	EFFECT OF REPETITIVE HIGH-DOSE TREATMENT WITH SOLUBLE COMPLEMENT RECEPTOR TYPE 1 AND COBRA VENOM FACTOR ON DISCORDANT XENOGRAFT SURVIVAL ^{1,2} . <i>Transplantation</i> , 1996, 62, 336-342.	1.0	49
39	Design, Synthesis, and Evaluation of A-, C-, and D-Ring Analogs of the Fungal Metabolite K-76 as Potential Complement Inhibitors. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 1437-1445.	6.4	23
40	The design, synthesis and evaluation of A,C,D-ring analogs of the fungal metabolite K-76 as complement inhibitors: a potential probe for the absolute stereochemistry at position 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 501-506.	2.2	11
41	THE EFFECT OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON HYPERACUTE REJECTION OF PORCINE XENOGRAFTS. <i>Transplantation</i> , 1994, 57, 363-370.	1.0	244
42	Characterization of monoclonal antibodies specific for the V β 23 family of the human T cell receptor generated using soluble TCR β -chain. <i>Journal of Immunological Methods</i> , 1993, 164, 233-244.	1.4	12
43	THE EFFECT OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON HYPERACUTE XENOGRAFT REJECTION. <i>Transplantation</i> , 1991, 52, 868-872.	1.0	140
44	Two Distinct Immunogenic Epitopes on the β Chain of Human T Cell Antigen Receptor. <i>Hybridoma</i> , 1989, 8, 577-588.	0.6	13
45	Terbium ion binding to a synthetic .gamma.-carboxyglutamic acid containing heptapeptide corresponding to bovine prothrombin residues 17-23. <i>Inorganic Chemistry</i> , 1986, 25, 4503-4506.	4.0	2
46	Mechanism of action of thrombin on fibrinogen. Kinetic evidence for involvement of aspartic acid at position P10. <i>Biochemistry</i> , 1983, 22, 4170-4174.	2.5	59
47	Mechanism of action of thrombin on fibrinogen. Direct evidence for the involvement of phenylalanine at position P9. <i>Biochemistry</i> , 1982, 21, 6167-6171.	2.5	45
48	Chemical modification of peptides containing .gamma.-carboxyglutamic acid. <i>Journal of Organic Chemistry</i> , 1982, 47, 1812-1816.	3.2	11
49	Tryptophan exposure in various conformational isomers of bovine prothrombin fragment 1. <i>Biochimica Et Biophysica Acta (BBA) - Protein Structure</i> , 1981, 667, 35-43.	1.7	4
50	Interaction of lanthanide(III) ions with bovine prothrombin fragment. 1. A luminescence and nuclear magnetic resonance study. <i>Journal of the American Chemical Society</i> , 1980, 102, 3413-3419.	13.7	14